MedTrace Logo

Apremilast Pregnancy Exposure Registry

NCT02775500 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 233

Last updated 2025-01-28

No results posted yet for this study

Summary

The purpose of the Apremilast Pregnancy Exposure Registry is to monitor planned and unplanned pregnancies exposed to apremilast and to evaluate the safety of this medication relative to specified pregnancy outcomes, and to evaluate potential effects of prenatal apremilast exposure on infant health status through one year of age.

Conditions

Interventions

DRUG

apremilast

Comparison of women exposed during pregnancy versus women who are not exposed to apremilast

Sponsors & Collaborators

Principal Investigators

  • Christina Chambers, PhD, MPH · UCSD

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2024-12-31
Completion
2025-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02775500 on ClinicalTrials.gov